Given the extensive body of evidence supporting the efficacy of PKM2 inhibition in tumor therapy, a systematic summary has been compiled, categorizing recent advancements into three primary strategies: direct targeting of PKM2 protein, modulation of PKM2-associated nuclear transcripts, and indirect inhibition via regulatory signaling pathways that modulate PKM2 activity. The gene discussed is PKM; the disease is neoplasm.